The epidermal growth factor receptor (EGFR) is one of the receptor tyrosine kinases. Some EGFRs are transferred from membrane to nucleus upon ligand binding and an increase of this translocation causes high-level expression of nuclear EGFR. The high-level expression of nuclear EGFR was reported to be a poor prognostic factor in various cancers such as breast cancer, ovarian cancer, gallbladder cancer, prostate cancer and oropharyngeal cancer. Regarding oral cancers, one report indicated that nuclear EGFR is detected in oral squamous cell carcinoma (OSCC) on immunohistochemical staining, but did not mention the clinicopathological prognostic value in detail. Therefore, we investigated the expression of nuclear EGFR in OSCC cell lines and primary tumor specimens of tongue SCCs to see whether nuclear EGFR could be a useful prognostic value. We verified the expression level of nuclear EGFR in OSCC cell lines and observed an increase in the amount of nuclear EGFR upon EGF stimulation with the expression level reaching its peak after 15 minutes. Nuclear EGFR positive tumors were found in 23 patients (28.0%) with tongue SCCs. However, we could not find any correlation between clinicopathological factors and the expression of nuclear EGFR in patients with tongue SCCs.
Download full-text PDF |
Source |
---|
J Am Chem Soc
December 2024
Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China.
PROTACs have emerged as a therapeutic modality for the targeted degradation of proteins of interest (POIs). Central to PROTAC technology are the E3 ligase recruiters, yet only a few of them have been identified due to the lack of ligandable pockets in ligases, especially among single-subunit ligases. We propose that binders of partner proteins of single-subunit ligases could be repurposed as new ligase recruiters.
View Article and Find Full Text PDFFront Oncol
December 2024
Department of Radiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Background: The aim of this study is to develop deep learning models based on F-fluorodeoxyglucose positron emission tomography/computed tomographic (F-FDG PET/CT) images for predicting individual epidermal growth factor receptor () mutation status in lung adenocarcinoma (LUAD).
Methods: We enrolled 430 patients with non-small-cell lung cancer from two institutions in this study. The advanced Inception V3 model to predict EGFR mutations based on PET/CT images and developed CT, PET, and PET + CT models was used.
<b>Background and Objective:</b> Cervical cancer is the second most common cancer in Indonesia, where traditional herbal treatments like <i>Zanthoxylum acanthopodium</i> (andaliman) are culturally used. Investigating protein biomarkers such as E7, pRb, EGFR and p16 can help assess the efficacy of these treatments. <b>Materials and Methods:</b> There were 5 groups in this study: 2 control groups (C- and C+) and 3 treatment groups (each receiving one of three doses).
View Article and Find Full Text PDFCurr Oncol
December 2024
Radiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, Italy.
A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases.
View Article and Find Full Text PDFThorac Cancer
December 2024
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Concurrent mutations in tumor protein p53 (TP53) or Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-pathway components are linked to poor outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), but the impact of triple mutations remains unclear. We report a case of EGFR-, TP53-, and Cullin 3 (CUL3)-mutant NSCLC in a 43-year-old woman with widespread metastases at diagnosis, including those in the contralateral lung, distant lymph nodes, pericardium, liver, bones, left adrenal gland, and brain. She received osimertinib as first-line therapy, but pericardial effusion and liver metastases progressed rapidly over 3 months, and she was switched to carboplatin and pemetrexed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!